基于模拟的沃里科纳的第一剂量设计的有效性和安全性
Takumi Umemura1, Hiromi Kakizaki2, Yoshikazu Mutoh3
1Department of Pharmacy, Tosei General Hospital, Seto, Aichi, Japan; Department of Clinical Infectious Diseases, Tosei General Hospital, Seto, Aichi, Japan; Department of Clinical Infectious Diseases, Aichi Medical University, Nagakute, Aichi, Japan; College of Pharmacy, Kinjo Gakuin University, Nagoya, Aichi, Japan.
与标准VRCZ治疗相比,初始沃里康纳 (VRCZ) 剂量的基于软件的模拟可以提高药物度并降低肝毒性. 这种方法提高了患者的安全性和治疗的有效性.
科学领域:
- 药理动力学和药理动力学
- 临床药理学 临床药理学
- 传染性疾病 传染性疾病
背景情况:
- 沃里康纳 (VRCZ) 是一种重要的抗真菌剂.
- 标准VRCZ剂量依赖于包装插入的建议.
- 优化初始VRCZ剂量可能会改善结果.
研究的目的:
- 为了比较基于软件模拟的初始VRCZ剂量的有效性和安全性,与标准的包装插件剂量相比.
- 评估VRCZ剂量设计对肝毒性和视觉症状的影响.
- 评估达到治疗VRCZ最低度的情况.
主要方法:
- 在一个单一中心进行回顾性观察研究 (2017年4月-2023年9月).
- 患者分为基于软件的模拟组和标准治疗组.
- 主要结局:肝毒性和视觉症状的发生率.
主要成果:
- 基于软件的模拟组在目标范围内 (1-4μg/mL) 实现了较低的初始VRCZ最低度.
- 在模拟组中,所有级别的肝毒性和视觉症状的发生率显著降低.
- 在基于软件的模拟组中,肝毒性≥2级的发生率降低.
结论:
- 使用模拟软件的初始VRCZ剂量设计可以提高达到适当的最低度.
- 与标准治疗相比,软件引导的VRCZ剂量导致显著肝毒性的发生较少.
- 模拟软件为优化VRCZ治疗提供了一个有希望的策略.
相关概念视频
Factors Affecting Drug Response: Overview
Dosage Regimen: Fixed Dose
Fixed-dose regimens can be used for various routes of administration, including intravenous (IV) injections and oral medications. For IV administration, a predetermined amount of the drug is...
One-Compartment Open Model for IV Bolus Administration: Estimation of Elimination Rate Constant, Half-Life and Volume of Distribution
Preclinical Development: Overview
One-Compartment Open Model for IV Bolus Administration: General Considerations
The drug's presence in the body is defined by an equation representing the difference between the rates of drug entry and exit. Key parameters—elimination rate constant,...
Drug Dosage Regimen: Overview
Typically, the starting dose and dosing interval are guided by the manufacturer's recommendations based on clinical trials conducted during and after drug...


